CD274 and non-small cell lung carcinoma: In non-Sq NSCLC, TMB and PD-L1 were independent biomarkers; across KRASm isoforms 49–62% had TMB ≥ 10 mutations/Mb or high PD-L1, but only 15–20% had both.